NUVB Q3 2024 Earnings — Nuvation Bio Inc. Revenue & Financial Results | Market Cap Arena

NUVBNuvation Bio Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$727,000

Gross Profit

-$788,000-108.4% margin

Operating Income

-$48M-6616.4% margin

Net Income

-$41M-5668.5% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

-49.3%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$572M

Total Liabilities

$69M

Stockholders' Equity

$503M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$727,000	$0	—
Gross Profit	-$788,000	$0	—
Operating Income	-$48M	-$26M	-82.6%
Net Income	-$41M	-$20M	-109.7%

Geographic Segments

JAPAN

$600,00086%

CHINA

$100,00014%